Stock Analysis, Dividends, Split History

CYH / Community Health Systems, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)380.18
Enterprise Value ($M)13,962.18
Book Value ($M)-879.00
Book Value / Share-7.56
Price / Book-0.43
NCAV ($M)-13,389.00
NCAV / Share-116.04
Price / NCAV-0.03
Share Statistics
Common Shares Outstanding 114,627,148
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 114,651,004
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.18
Return on Assets (ROA)-0.11
Return on Equity (ROE)-1.48
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.79
Income Statement (mra) ($M)
Health Care Organization Revenue18,398,000,000.00
Disposal Group Including Discontinued Operation Revenue79,000,000.00
Health Care Organization Patient Service Revenue Provisionfor Bad Debts3,045,000,000.00
Health Care Organization Revenue Net Of Patient Service Revenue Provisions15,353,000,000.00
Operating Income-1,878.00
Net Income-2,396.00
Earnings Per Share Basic-22.00
Earnings Per Share Diluted-22.00
Cash Flow Statement (mra) ($M)
Cash From Operations773.00
Cash from Investing1,069.00
Cash from Financing1,069.00
Identifiers and Descriptors
Central Index Key (CIK)1108109
Related CUSIPS
203668908 203668116 203668958

Split History

Stock splits are used by Community Health Systems, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

HYG And U.S. High-Yield Market Outlook: Week Ending September 16, 2018

20h seekingalpha
HYG was up 74 bps on the last week compared to significant value loss in a week before. (25-0)

Will Hurricane Florence Hurt LifePoint's Patient Volumes?

2018-09-13 zacks
LifePoint Health Inc. (LPNT - Free Report) has high exposure to Hurricane Florence, with 30% of its beds in North and South Carolina, which is within the forecast path of the storm, as per analysts as pointed out in CNBC news. This makes the stock vulnerable to earnings miss in the third quarter. Other companies to face the wrath include Community Health Systems, Inc. (CYH - Free Report) , HCA Healthcare, Inc. (31-0)

Community Health Systems (CYH) Presents at Baird's Global Healthcare Conference - Slideshow

2018-09-07 seekingalpha
The following slide deck was published by Community Health Systems, Inc. in conjunction with this event. (25-0)

Is the Options Market Predicting a Spike in Community Health (CYH) Stock?

2018-09-05 zacks
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (25-0)

8 Cheap Stocks That Cost Less Than $10

2018-08-30 investorplace
Cheap stocks are never “sure things.” There are many cheaply traded companies, even penny stocks, under $10 right now that deserve to be there and will only get cheaper. (110-2)

CUSIP: 203668108